20:07 , Oct 5, 2018 |  BC Week In Review  |  Company News

Chugai grants Lilly rights to preclinical diabetes candidate

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) granted Eli Lilly and Co. (NYSE:LLY) worldwide rights to develop and commercialize preclinical Type II diabetes candidate OWL833. Chugai will receive $50 million up front and is eligible for undisclosed...
19:12 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Lilly debuts data for new Type II diabetes candidate

Eli Lilly and Co. (NYSE:LLY) reported data from a Phase IIb trial in Type II diabetics showing that high-dose LY3298176 led to improvements in HbA1c and weight loss that were better than those seen to...
20:24 , Oct 4, 2018 |  BC Extra  |  Clinical News

Novo takes hit as Lilly debuts data for new diabetes candidate

Eli Lilly and Co. (NYSE:LLY) reported data from a Phase IIb trial in Type II diabetics Thursday showing that high-dose LY3298176 led to improvements in HbA1c and weight loss that were better than those seen...
16:38 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Zealand's hypoglycemia candidate meets in second Phase III

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said dasiglucagon (ZP4207) met the primary endpoint in a second Phase III trial to treat severe hypoglycemia in patients with Type I diabetes. The trial is evaluating a liquid formulation...
22:43 , Sep 13, 2018 |  BC Week In Review  |  Company News

Zealand brings in $205M for pipeline via royalty pharma deal

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million. Sanofi...
16:36 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Novo's oral GLP-1 analog meets primary in Phase IIIa diabetes, renal impairment study

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported that oral semaglutide met the primary endpoint in the Phase IIIa PIONEER 5 trial to treat Type II diabetes and moderate renal impairment. Compared with placebo, the oral...
23:38 , Sep 6, 2018 |  BC Extra  |  Company News

Zealand brings in $205M for pipeline via Royalty Pharma deal

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million....
00:21 , Aug 10, 2018 |  BC Week In Review  |  Company News

Novo Nordisk's Tresiba, Victoza sales disappoint amid sliding U.S. sales

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) shares dipped Aug. 8 after reporting narrowing U.S. sales and disappointing revenues for diabetes drugs Tresiba insulin degludec and Victoza liraglutide in its 2Q18 earnings. Novo also predicted lower...
21:35 , Aug 8, 2018 |  BC Extra  |  Company News

Novo Nordisk's Tresiba, Victoza sales disappoint amid sliding U.S. sales

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) shares dipped Wednesday after reporting declining U.S. sales and disappointing revenues for diabetes drugs Tresiba insulin degludec and Victoza liraglutide in its 2Q18 earnings. Novo also predicted lower U.S....
17:59 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Neuraly raises $36M series A to develop microglia-targeted PD candidate

Neurodegeneration company Neuraly Inc. (Germantown, Md.) launched July 18 with a tranched $36 million series A round led by new investor D&D Pharmatech (Gyeonggi-do, Korea). Korean venture funds Smilegate, InterVest, LB Investment, Magna Investment, Geon...